Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System

Hohenforst-Schmidt, Wolfgang; Linsmeier, Bernd; Kioumis, Ioannis; Li, Qiang; Huang, Haidong; Sachpatzidou, Despoina; Lampaki, Sofia; Organtzis, John; Domvri, Kalliopi; Sakkas, Leonidas; Zachariadis, George A.; Archontas, Konstantinos N.; Kallianos, Anastasios; Rapti, Aggeliki; Yarmus, Lonny; Zarogoulidis, Konstantinos; Brachmann, Johannes

doi:10.7150/jca.9021

Cited by 15 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The jet nebulizer maxineb with the residual cup “J” was used for the administration of aerosol nivolumab and aerosol cisplatin based on our previous experiments. 24 Figure 1 . (supplementary data attached to the submission)…”

Section: αNimals and Methodsmentioning

confidence: 99%

Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination

et al. 2018

Self Cite

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death after prostate cancer for males and breast cancer for females. There are novel therapies in the past five years such as; tyrosine kinase inhibitors and most recently in the last two years immunotherapy. Immunotherapy is currently being investigated if it can be administered alone or in combination. Previously we have investigated whether immunotherapy compounds can be produced as aerosols, and in the current study we investigated the safety and efficiency independently of the programmed death-ligand 1. The aerosol administration of both cisplatin and nivolumab is possible. The combination of the two drugs has a synergistic effect and therefore should be considered an option. Time of administration for immunotherapy is also very important.

show abstract

Section: αNimals and Methodsmentioning

confidence: 99%

Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The cell doubling time was 21 hours. 22 , 42 – 46 At confluence, the cells were harvested with 0.25% trypsin and then resuspended at 1.5×10 6 cells in 0.15 mL of phosphate-buffered saline (Biochrom) that was injected into the mice. The suspension was inoculated subcutaneously (using a 27-gauge needle, 1.5×10 6 cells) into the back of each mouse ( Figure 1 ).…”

Section: Animals and Methodsmentioning

confidence: 99%

DDMC-p53 gene therapy with or without cisplatin and microwave ablation

Hohenforst-Schmidt¹,

Stopek²,

Vogl³

et al. 2015

OTT

Self Cite

View full text Add to dashboard Cite

Lung cancer remains the leading cause of death in cancer patients. Severe treatment side effects and late stage of disease at diagnosis continue to be an issue. We investigated whether local treatment using 2-diethylaminoethyl-dextran methyl methacrylate copolymer with p53 (DDMC-p53) with or without cisplatin and/or microwave ablation enhances disease control in BALBC mice. We used a Lewis lung carcinoma cell line to inoculate 140 BALBC mice, which were divided into the following seven groups; control, cisplatin, microwave ablation, DDMC-p53, DDMC-p53 plus cisplatin, DDMC-p53 plus microwave, and DDMC-p53 plus cisplatin plus microwave. Microwave ablation energy was administered at 20 W for 10 minutes. Cisplatin was administered as 1 mL/mg and the DDMC-p53 complex delivered was 0.5 mL. Increased toxicity was observed in the group receiving DDMC-p53 plus cisplatin plus microwave followed by the group receiving DDMC-p53 plus cisplatin. Infection after repeated treatment administration was a major issue. We conclude that a combination of gene therapy using DDMC-p53 with or without cisplatin and microwave is an alternative method for local disease control. However, more experiments are required in a larger model to identify the appropriate dosage profile.

show abstract

“…Co-administration of multiple drugs may offer higher therapeutic efficacy than monotherapy. − This is supported by an earlier study, which used double-walled polymeric microspheres to co-deliver doxorubicin with a therapeutic transgene (encoding the p53 tumor suppressor protein, and being complexed with chitosan nanoparticles) to human hepatocellular carcinoma HepG2 cells. Not only was the combined treatment found to enhance cytotoxicity more effectively than either of the two therapies alone, but also the overexpression of p53 could promote caspase-3 activation, further enhancing the antiproliferative effect of doxorubicin .…”

Section: Introductionmentioning

confidence: 93%

“…Not only was the combined treatment found to enhance cytotoxicity more effectively than either of the two therapies alone, but also the overexpression of p53 could promote caspase-3 activation, further enhancing the antiproliferative effect of doxorubicin . More recently, the promising potential of multidrug therapy is shown in vivo by the observation that administration of a therapeutic transgene, using adenoviral-type 5(dE1/E3) (Cytomegalovirus promoter), before administration of aerosol cisplatin can increase the expression of ATP-binding cassette (ABC) proteins in the respiratory system to enhance the therapeutic effect of the drug . These studies have demonstrated the potential of the multidrug treatment regimen in enhancing the therapeutic efficacy.…”

Section: Introductionmentioning

confidence: 99%

Multicompartment Microgel Beads for Co-Delivery of Multiple Drugs at Individual Release Rates

Lai

Susha

Rogach

2015

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Multidrug therapy may yield higher therapeutic effects as compared to monotherapy, yet its wide application has been hampered by the limitations of conventional drug delivery systems, in which not only incompatible drugs cannot be co-delivered but also the release rates of individual co-delivered drugs cannot be tuned separately. Regarding these limitations, we adopt the microfluidic electrospray technology to fabricate alginate-based multicompartment microgel beads. By using cadmium-telluride (CdTe) quantum dots (QDs) and a quenching agent as a model pair, the beads are shown to effectively separate incompatible drugs during co-delivery, and significantly prolong the time of observable fluorescence emission from QDs co-delivered with a quenching agent. Moreover, the drug release rates from different compartments can be tuned using the polymer blending technique to achieve a variety of drug release patterns. This study is one of the first to adopt the microfluidic electrospray technology to generate microgel beads with such versatility for co-delivery of multiple drugs. Our results provide evidence for the promising potential of our beads to be further developed as a carrier for multidrug therapy and other applications that require co-administration of multiple bioactive agents.

show abstract

Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System

Cited by 15 publications

References 48 publications

Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination

Aerosol Immunotherapy with or without Cisplatin for metastatic lung cancer non-small cell lung cancer disease: In vivo Study. A more efficient combination

DDMC-p53 gene therapy with or without cisplatin and microwave ablation

Multicompartment Microgel Beads for Co-Delivery of Multiple Drugs at Individual Release Rates

Contact Info

Product

Resources

About